With the growing appreciation that changes to specific molecules can reflect the broader biochemical anomalies arising from the cancer state, the study of lipids and small-molecule metabolites has become increasingly important for cancer research. The objective of the Virginia Commonwealth University (VCU) Lipidomics/Metabolomics Core (VLMC) is therefore to provide cost effective lipid and small-metabolite analyses for VCU Massey Cancer Center (MCC) members. The VLMC supports the ability of MCC members to qualitatively and highly quantitatively investigate the lipidome and metabolome both in vitro and in vivo studies involving cancer cell lines, preclinical animal models of cancer, and/or patients with cancer. The VLMC does so by providing and maintaining a dedicated advanced lipidomic and metabolomic instrumentation suite that is nationally competitive. Specifically, the VLMC maintains 4 advanced QTRAP-type mass analyzers, each equipped with an ultra-performance liquid chromatography (UPLC) system. An additional quadrupole time-of- flight mass analyzer is equipped with a differential mobility source and a UPLC. In addition to instrumentation, the VLMC has developed, deployed, and proven state-of-the-art methodologies that contemplate overlapping targeted, semi-targeted, and non-targeted approaches to the identification and quantification of changes to the lipidome and metabolome in a high-throughput fashion and over a large dynamic range. The resource is directed by Charles Chalfant, PhD, who is supported by the technical director, D. Shanaka Wijesinghe, PhD, and an additional 2.0 FTEs. The resource director and/or staff support MCC programmatic science by providing consultative services for experimental design and data interpretation, method development, education to certify end-users in the use of the equipment, operator-assisted analysis, and instrument maintenance. The VLMC is a jointly managed (MCC and VCU) resource within close walking distance of MCC. Standard hours for the facility are 9:00 AM until 5:00 PM, Monday through Friday, with certified users enjoying access 24 hours per day, 7 days per week. The usage of services and equipment is tracked and charged back. The VLMC adds significant value to MCC research by providing services that are critical to addressing the research questions of MCC members, services that otherwise would not be practically obtainable or would be cost prohibitive through alternative vendors or even other non-profit institutions. Overall, the instrumentation and expertise available in the VLMC have facilitated the development of a growing user base of MCC members, whose cancer-related research routinely garners peer-reviewed national funding and is published in high-impact scientific journals.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
2P30CA016059-36
Application #
9277724
Study Section
Subcommittee A - Cancer Centers (NCI-A)
Project Start
Project End
Budget Start
2017-05-01
Budget End
2018-04-30
Support Year
36
Fiscal Year
2017
Total Cost
$55,676
Indirect Cost
$19,659
Name
Virginia Commonwealth University
Department
Type
Domestic Higher Education
DUNS #
105300446
City
Richmond
State
VA
Country
United States
Zip Code
23298
Cantwell, Marc T; Farrar, Jared S; Lownik, Joseph C et al. (2018) STAT3 suppresses Wnt/?-catenin signaling during the induction phase of primary Myf5+ brown adipogenesis. Cytokine 111:434-444
Yamada, Akimitsu; Nagahashi, Masayuki; Aoyagi, Tomoyoshi et al. (2018) ABCC1-Exported Sphingosine-1-phosphate, Produced by Sphingosine Kinase 1, Shortens Survival of Mice and Patients with Breast Cancer. Mol Cancer Res 16:1059-1070
Volker, Sonja E; Hedrick, Shannon E; Feeney, Yvonne B et al. (2018) Cyclophilin A Function in Mammary Epithelium Impacts Jak2/Stat5 Signaling, Morphogenesis, Differentiation, and Tumorigenesis in the Mammary Gland. Cancer Res 78:3877-3887
Aqbi, Hussein F; Wallace, Matthew; Sappal, Samay et al. (2018) IFN-? orchestrates tumor elimination, tumor dormancy, tumor escape, and progression. J Leukoc Biol :
Durant, Stephen T; Zheng, Li; Wang, Yingchun et al. (2018) The brain-penetrant clinical ATM inhibitor AZD1390 radiosensitizes and improves survival of preclinical brain tumor models. Sci Adv 4:eaat1719
Li, Xiaojiaoyang; Liu, Runping; Huang, Zhiming et al. (2018) Cholangiocyte-derived exosomal long noncoding RNA H19 promotes cholestatic liver injury in mouse and humans. Hepatology 68:599-615
Wang, Feng; Li, Hongyan; Markovsky, Ela et al. (2018) Pazopanib radio-sensitization of human sarcoma tumors. Oncotarget 9:9311-9324
Damle, S R; Martin, R K; Cockburn, C L et al. (2018) ADAM10 and Notch1 on murine dendritic cells control the development of type 2 immunity and IgE production. Allergy 73:125-136
Stokes, Nancy A; Stanciu, Cristina E; Brocato, Emily R et al. (2018) Simplification of complex DNA profiles using front end cell separation and probabilistic modeling. Forensic Sci Int Genet 36:205-212
Poklepovic, Andrew; Qu, Yuesheng; Dickinson, Molly et al. (2018) Randomized study of doxorubicin-based chemotherapy regimens, with and without sildenafil, with analysis of intermediate cardiac markers. Cardiooncology 4:

Showing the most recent 10 out of 586 publications